MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (āCircassiaā or āthe Companyā), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium ...
Each actuation provides a metered dose of 12mg of the formulation which contains lactose monohydrate as the carrier, 400mcg of aclidinium bromide, and 12mcg of formoterol fumarate. Duaklir Pressair ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
MORRISVILLE ā Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has commercially launched Duaklir, a maintenance treatment for patients with chronic obstructive ...
MISSISSAUGA, ON, Oct. 29, 2015 /CNW/ - AstraZeneca Canada announced today that DUAKLIR ā¢ GENUAIR ® (aclidinium bromide/formoterol fumarate dihydrate 400/12 Ī¼g) is now available in Canada for the ...
Oxford, UK - 7 September 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive ...
Circassia announced that the Food and Drug Administration (FDA) has approved Duaklir Pressair (aclidinium bromide, formoterol fumarate) for the maintenance treatment of COPD. Circassia announced that ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
Duaklir is a dual-acting inhaler for COPD. At launch, it would be the fifth such product in the market. To attract patients, the campaign focused on details, and talked about how the device was more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results